TransMedics Group (TMDX) Tops Q4 EPS by 9c; Guides FY23 Reveneus Above Views

TransMedics Group (NASDAQ: TMDX) reported Q4 EPS of ($0.21), $0.09 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $31.4 million versus the consensus estimate of $24.45 million.

GUIDANCE:

TransMedics Group sees FY2023 revenue of $138-145 million, versus the consensus of $134.71 million.

For earnings history and earnings-related data on TransMedics Group (TMDX) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Stitch Fix (SFIX) Tops Q3 EPS by 4c, Offers Guidance
• Lands' End (LE) Tops Q1 EPS by 8c ; Offers Guidance